Physician profile
Veronica Mardo
NPI 1992927982
$525.55
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $218 · 2020: $100 · 2021: $172 · 2022: $35.48.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $155.03 | 2019-2020 | |
| Abbvie INC. | $82.83 | 2020-2022 | |
| Novo Nordisk INC | $50.14 | 2019-2020 | |
| Pfizer INC. | $40.78 | 2019-2021 | |
| Dexcom, INC. | $37.76 | 2021 | |
| Janssen Pharmaceuticals, INC | $28.46 | 2021-2022 | |
| Abbott Laboratories | $28.04 | 2021 | |
| Glaxosmithkline, LLC. | $21.21 | 2019 | |
| Gilead Sciences, INC. | $21.19 | 2020 | |
| Astellas Pharma US INC | $21.16 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $20.27 | 2021 | |
| Amgen INC. | $18.68 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veronica Mardo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.